Nanoparticle formulation increases Syzygium cumini antioxidant activity in Candida albicans-infected diabetic rats

Pharm Biol. 2017 Dec;55(1):1082-1088. doi: 10.1080/13880209.2017.1283338.

Abstract

Context: Syzygium cumini (L.) Skeels (Myrtaceae) is a medicinal plant widely used in folk medicine for the treatment of diabetes mellitus (DM). However, studies on the use of this plant and of nanoparticle formulations against DM-related fungal infections are scarce.

Objective: To evaluate the effect of the treatments with aqueous seed extract of S. cumini (ASc) and ASc-loaded polymeric nanoparticles (NPASc) on biochemical parameters in Candida albicans-infected diabetic rats.

Materials and methods: Male Wistar rats were divided into eight groups: Control, DM, C. albicans, C. albicans + ASc, C. albicans + NPASc, DM + C. albicans, DM + C. albicans + ASc and DM + C. albicans + NPASc. Rats were daily treated with ASc or NPASc (100 mg/kg) for 21 days. Biochemical parameters in serum and urine, advanced oxidation protein product (AOPP) and TBARS levels in the serum, kidney, liver and pancreas and N-acetyl-β-d-glucosaminidase (NAG) activities in kidney and urine were evaluated.

Results: Biochemical and oxidative stress parameters increased in rats with DM and/or candidiasis. NPASc was more effective than ASc in decreasing glucose (56%), cholesterol (33%) and creatinine (51%) levels; serum (16%) and pancreatic (46%) AOPP and renal (48%) TBARS levels when compared with DM + C. albicans group. In C. albicans group, both treatments decreased NAG activity but did not decrease creatinine levels.

Conclusions: These data suggest that the use of nanotechnology is able to improve plant extract properties such as antioxidant activity that may be useful in diabetes-related complications.

Keywords: Advanced oxidation protein product; N-acetyl-β-d-glucosaminidase; TBARS; animal models; diabetic complications; streptozotocin.

MeSH terms

  • Animals
  • Antifungal Agents / chemistry
  • Antifungal Agents / isolation & purification
  • Antifungal Agents / pharmacology*
  • Antioxidants / chemistry
  • Antioxidants / isolation & purification
  • Antioxidants / pharmacology*
  • Biomarkers / blood
  • Biomarkers / urine
  • Candida albicans / drug effects*
  • Candidiasis / blood
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology
  • Candidiasis / urine
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / urine
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / chemically induced
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / urine
  • Drug Compounding
  • Kidney / drug effects
  • Kidney / metabolism
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Nanoparticles*
  • Oxidative Stress / drug effects*
  • Pancreas / drug effects
  • Pancreas / metabolism
  • Phytotherapy
  • Plant Extracts / chemistry
  • Plant Extracts / isolation & purification
  • Plant Extracts / pharmacology*
  • Plants, Medicinal
  • Rats, Wistar
  • Seeds
  • Solvents / chemistry
  • Streptozocin
  • Syzygium / chemistry*

Substances

  • Antifungal Agents
  • Antioxidants
  • Biomarkers
  • Plant Extracts
  • Solvents
  • Streptozocin

Grants and funding

The authors wish to thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico [CNPq-Pq303245/2014-0]. The first author acknowledges the fellowship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).